Corcept Therapeutics Incorporated (CORT)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	140,686	141,295	125,983	118,023	106,140	91,386	94,616	94,500	101,418	116,870	112,733	111,844	112,512	106,453	97,607	99,411	106,011	109,398	114,113	105,972
Total assets	US$ in thousands	840,553	784,257	714,555	655,935	621,517	594,022	524,625	617,848	583,430	533,255	496,364	468,123	423,756	585,399	568,480	552,398	571,731	534,125	497,823	445,494
ROA		16.74%	18.02%	17.63%	17.99%	17.08%	15.38%	18.03%	15.30%	17.38%	21.92%	22.71%	23.89%	26.55%	18.18%	17.17%	18.00%	18.54%	20.48%	22.92%	23.79%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $140,686K ÷ $840,553K
= 16.74%

Corcept Therapeutics Incorporated's return on assets (ROA) has fluctuated over the period from March 31, 2020, to December 31, 2024. The ROA stood at 23.79% as of March 31, 2020, and showed a slight decrease to 22.92% by June 30, 2020. Subsequently, there was a declining trend in the ROA figures, with values of 20.48% as of September 30, 2020, and 18.54% as of December 31, 2020.

The ROA continued to decrease in the following periods, reaching a low of 15.30% as of March 31, 2023. However, there was a slight improvement in the ROA in the subsequent quarters, with the figure increasing to 18.03% as of June 30, 2023, and further to 17.08% by December 31, 2023.

As of December 31, 2024, Corcept Therapeutics' ROA stood at 16.74%. Overall, the fluctuations in the ROA indicate varying levels of efficiency in generating profits from the company's assets during the period under review. It is essential for stakeholders to monitor these trends to assess the company's operational performance and financial health.